Aurinia announces FDA acceptance of NDA filing and priority review for voclosporin to treat lupus nephritis

This article was originally published here

The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action

The post Aurinia announces FDA acceptance of NDA filing and priority review for voclosporin to treat lupus nephritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply